diaphoresis, tachycardia, agitation, and anxiety. Benzodiazepines, which enhance GABA activity, are the mainstay for treating AWS. However, even with liberal benzodiazepine use, patients can develop severe complications associated with AWS, including withdrawal seizures, Wernicke-Korsakoff syndrome, and alcohol withdrawal delirium.
Alcohol withdrawal delirium, also known as DT, has been estimated to occur in approximately 5% of patients hospitalized for alcohol withdrawal. 2 The diagnosis of DT is made when a patient meets the criteria for both alcohol withdrawal and delirium. 4 Delirium tremens typically occurs 72 hours after the development of AWS and lasts approximately 1 week. Early recognition and appropriate treatment of AWS are crucial to prevent DT. The mortality rate in patients with DT is reported to be as high as 15%, but with improved recognition and treatment, these rates are now estimated to be much lower. 2 , 5 Death associated with DT is generally secondary to complications from seizure, hyperthermia, and/or cardiac arrhythmias. Predictors for the development of DT include the presence of severe withdrawal symptoms, hypokalemia, and thrombocytopenia. Obtaining a thorough social and medical history is important as prior history of severe AWS, recent/past alcoholrelated seizures, and previous DT is also predictive of DT. 2 The management of DT mainly relies on the continuation of benzodiazepines to help control agitation and autonomic hyperactivity. However, escalating or cumulative doses of benzodiazepines may necessitate endotracheal intubation and mechanical ventilation if oversedation occurs. Although no specific benzodiazepine is recommended for treatment of DT, caution should be used when high doses of intravenous (IV) lorazepam are necessary, especially when administered as a continuous infusion. Intravenous lorazepam is formulated in propylene glycol. Accumulation of propylene glycol can lead to toxicity, which may present with lactic acidosis, cardiac instability, and multisystem organ dysfunction. Elevated propylene glycol levels and associated toxicity have been reported with lorazepam doses over 268 mg in a 24-hour time period and with infusion rates of greater than 12 mg/h. 6 Benzodiazepines with a long half-life, metabolized via the cytochrome P450 system (eg, diazepam, chlordiazepoxide), should be avoided in patients with significant liver dysfunction or advanced age because of the risk of drug accumulation in the body, resulting in oversedation. In the past several years, dexmedetomidine, a centrally acting alpha-2 agonist, has increasingly been used to treat AWS. 3 Dexmedetomidine has been shown to reduce benzodiazepine requirements during the early treatment of severe AWS, which theoretically may reduce the need for intubation and secondary complications from mechanical ventilation. Yet, although this is a possible benefit, because dexmedetomidine does not possess GABA activity, there is a risk that the reduced use of benzodiazepines may result in withdrawal seizures or the development of DT. More research is needed to assess the risks and benefits of dexmedetomidine use in the ICU for AWS and DT. Several other agents may have possible benefit for the management of refractory DT when benzodiazepine monotherapy is not adequate. The addition of the sedative propofol for intubated patients or the barbiturate phenobarbital may provide benefit as a result of their effect on the GABA receptor. 7 , 8 Propofol also reduces glutamatergic hyperactivity via NMDA receptor antagonism, providing additional mechanistic benefits for its use in AWS. Ketamine is another NMDA receptor antagonist reported to provide benefit when combined with benzodiazepines for DT. However, these data are from one small retrospective chart review with several limitations, and further data are required before ketamine can be recommended for DT. 9 In addition, ketamine should be avoided if a patient is experiencing hallucinations, as this medication may worsen these symptoms. Antiepileptic drugs, including carbamazepine and valproate, also have been described as beneficial in AWS; however, their role in the setting of DT is not clear. Antipsychotics may be used for agitation or hallucinosis associated with DT, but caution is advised as this class of medication may prolong the corrected QT interval and/or lower the seizure threshold. In conjunction with benzodiazepines, β -blockers may be used to target the adrenergic symptoms of DT. 5 , 10 Nonpharmacological interventions known to reduce the risk or duration of delirium, such as restoration of sleep-wake cycle and early mobilization, should be routinely implemented.
Serotonin Syndrome
Serotonin syndrome is a potentially fatal adverse drug reaction due to excess serotonergic activity in the nervous system. 11 The syndrome is often caused by concomitant use of multiple serotonin-active medications and may occur at therapeutic doses, in overdose situations, or as a result of drug-drug interactions. The precise incidence of serotonin syndrome in the ICU is difficult to quantify but is likely on the rise as a result of increased recognition of the reaction and increasing use of serotonergic medications. The 2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System reported 55 478 exposures to serotonin syndrome reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors with 119 fatal exposures, most associated with co-ingestion of other substances. 12 Another report estimated the incidence of serotonin syndrome in patients who overdose on SSRIs at approximately 14%. 11 The estimated mortality rate in patients who experience serotonin syndrome is 2% to 12%. 13 Serotonin, or 5-hydroxytryptamine (5-HT), is a neurotransmitter synthesized in the body and is regulated via multiple homeostatic mechanisms. Excess serotonin is eliminated by the pulmonary or hepatic endothelium, so in settings of peripheral or pulmonary endothelial damage the capacity to metabolize excess serotonin may be impaired. This alteration of serotonin metabolism, in combination with the use of serotonergic medications, may contribute to the development of serotonin syndrome in critically ill patients. In the ICU, serotonin syndrome is typically associated with the use of 2 or more concomitant serotonergic medications, although it has been reported with monotherapy. A wide variety of medications have been implicated in serotonin syndrome development, including antidepressants, antimicrobials, drugs of abuse, anticonvulsants, analgesic drugs, and antiemetic drugs ( Table 2 ) . 11 The classic triad of serotonin syndrome includes altered mental status, autonomic hyperactivity, and neuromuscular abnormalities. Clonus (inducible, spontaneous, and ocular) is the most sensitive and specific sign in the diagnosis of serotonin syndrome.
11 Several diagnostic criteria have been developed, including the Hunter Serotonin Toxicity Criteria 14 and Sternbach Criteria, 15 which include assessment for clonus, agitation, diaphoresis, hyperthermia, and hyperreflexia ( Table 3 ). Other common features include hyperactive bowel sounds and mydriasis. Exposure to a serotonergic agent in addition to a positive clinical examination is essential to diagnose serotonin syndrome. Symptoms develop rapidly, often within 24 hours of medication exposure or dose escalation and range from mild to life-threatening. Assessing the temporal relationship between medication exposure and symptom onset is an important factor that can help differentiate serotonin syndrome from other hyperthermic crises (eg, NMS).
Initial management of serotonin syndrome includes withdrawal of serotonergic medications and supportive care. Symptoms may resolve within 24 hours of discontinuing the inciting medication(s), although symptoms can be prolonged when medications with long elimination half-lives, such as the SSRI fluoxetine, are involved. Control of agitation with benzodiazepines is important to prevent ongoing muscle breakdown and acidosis. Physical restraints should be avoided to prevent prolonged muscle contraction, which may result in consequential lactic acidosis and hyperthermia. In severe cases, cooling and intubation allowing for deep sedation and paralysis may be required to attenuate refractory hyperthermia. A nondepolarizing paralytic such as rocuronium is preferred over succinylcholine to avoid the risk of hyperkalemia and arrhythmias if rhabdomyolysis is present. Antipyretics are rarely effective for hyperthermia associated with serotonin syndrome because the hyperthermia is caused by muscular activity rather than a change in hypothalamic temperature set point. Cyproheptadine, an antihistamine, exhibits 5-HT 2 antagonism at high doses (12-18 mg/d) and may be considered in patients with moderate to severe symptoms. 20 It has been shown to be beneficial in case series, although its efficacy has not been rigorously evaluated in large, well-conducted studies. Various dosing strategies for cyproheptadine have been described but an initial dose of 12 mg by mouth followed by 2 mg every 2 hours may be used in the initial phase of treatment with a typical maintenance dose of 4 to 8 mg every 6 hours. 11 Olanzapine and chlorpromazine have been used for their 5-HT antagonistic effects, but their efficacy is not well established. In addition, antipsychotics should not be used for serotonin syndrome until NMS has been ruled out.
Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome is a rare but life-threatening complication associated with the use of dopamine antagonists or after abrupt withdrawal of dopaminergic agents. 21 Agents that are more commonly implicated with the development of NMS are the older first-generation antipsychotics, including haloperidol. However, the second-generation antipsychotics have also been associated with the development of NMS. Besides antipsychotics, any medication that blocks dopamine has the potential to precipitate NMS; examples include metoclopramide, promethazine, and droperidol. The abrupt withdrawal of dopaminergic medications for Parkinson disease has also been implicated with inducing NMS.
Neuroleptic malignant syndrome is most often characterized by the presence of muscle rigidity, hyperthermia, and altered mental status after the initiation or dose increase of a causative agent. Multiple sets of criteria have been developed to diagnose NMS, but all have similar core features ( Table 3 ). The American Most commonly used scale; consists of 23 items (the presence of at least 2 of the fi rst 14 items is necessary to defi ne a case) 1. Items 1 through 14 used for screening: excitement, immobility/stupor, mutism, staring, posturing, grimacing, echopraxia/echolalia, stereotypic movements, mannerisms, repetition of words/phrases, rigidity, negativism, waxy fl exibility, refusal to eat/ drink/make eye contact 2. Items 15 through 23: Additional items include impulsivity, exaggerated cooperation with a requested movement, raising arm in response to light pressure but with instruction not to raise arm, resistance to passive movement that is equal in strength to force applied and is automatic versus willful, appears stuck or has hesitant movement, grasp refl ex, preservation, combativeness, autonomic abnormalities 3. All items (1 through 23) are scored from 0 to 3 points to assess overall severity (total score ranges 0 to 69) Abbreviations: DBP, diastolic blood pressure; ECT, electroconvulsive therapy; HR, heart rate; NMS, neuroleptic malignant syndrome; SBP, systolic blood pressure.
Psychiatric Association describes that NMS can be diagnosed when both hyperthermia and muscle rigidity are present along with at least 2 other notable symptoms that are not explained by other medical causes or mental disorders. 4 These other signs or symptoms associated with NMS include autonomic instability, tremor, leukocytosis, or elevated creatine kinase (as a sign of muscle breakdown, a consequence of ongoing muscle rigidity). Neuroleptic malignant syndrome may be mistaken for other psychiatric or medical emergencies, such as serotonin syndrome or malignant hyperthermia; however, the absence of myoclonus and lack of recent use of anesthetic or induction agents can be helpful in distinguishing them from NMS, respectively. Symptoms of NMS usually present within 2 weeks of drug initiation or dose increase and can persist for approximately 10 days after discontinuation of the offending agent (or multiple weeks following administration of most long-acting injectable antipsychotics). 21 , 22 The incidence and mortality rates of NMS have dropped significantly, most likely as a result of the development of secondgeneration antipsychotics and greater recognition of the illness. Prior to 1984, mortality rates were reported to be as high as 25%. More recent mortality estimates are approximately 3% to 16%, for second-generation antipsychotics and older agents, respectively. 23 , 24 The initial management of early and mild NMS includes supportive care, benzodiazepines, and restoration of dopamine activity by discontinuation of the offending agent or resuming a dopaminergic agent that may have been withheld. However, for progressive or moderate to severe NMS, other agents may be initiated including bromocriptine or amantadine and dantrolene. No intervention has been evaluated in a large, well-conducted study, and therefore conclusions about their efficacy are based on case reports or observational data. Bromocriptine is an ergot alkaloid that is structurally similar to dopamine and exerts its effects through postsynaptic dopamine-receptor stimulation. 22 Because bromocriptine works by restoring dopaminergic function, it may reduce many symptoms associated with NMS, including muscle rigidity, hyperthermia, autonomic lability, and altered mental status. The use of bromocriptine is thought to reduce both recovery time and mortality rate when used alone or in combination with other therapies. 25 Usual starting doses of bromocriptine range from 2.5 to 5 mg by mouth every 8 to 12 hours, titrating on the basis of the resolution of symptoms, up to 45 to 60 mg/d. 22 , 25 Initiation of therapy is most beneficial early in the disease course when symptoms are at peak severity. Amantadine 200 to 400 mg in divided doses is also a dopaminergic medication that has been reported to have benefit in the treatment of NMS. 25 Bromocriptine and amantadine are available only in an oral formulation that must be administered by either mouth or gastric tube.
Dantrolene is a peripheral skeletal muscle relaxant thought to help with muscle rigidity and hyperthermia associated with NMS. Its use is commonly reserved for cases of severe NMS when significant muscle rigidity and associated sequelae are present. 25 The usual dose of dantrolene is 1 to 2.5 mg/kg administered IV as a bolus, followed by 1 mg/kg IV every 6 hours if the bolus is effective at reducing symptoms. This dose is tapered slowly over days to weeks and can be converted to the oral formulation of dantrolene when feasible. Similar to bromocriptine, dantrolene use has been associated with a reduced recovery time and decreased mortality rate when compared with supportive therapy alone. 25 Patients receiving dantrolene should have liver function tests monitored as a result of a low risk of hepatotoxicity with the medication.
Electroconvulsive therapy (ECT) also has been used in the setting of severe NMS and has been shown to be effective when conventional drug therapy fails. The exact mechanism of ECT is unknown. Other agents reported to demonstrate benefit in NMS but not commonly used include levodopa/carbidopa, apomorphine, and barbiturates. 26 Anticholinergic agents should be avoided in moderate to severe illness as they can worsen NMS. 27 For patients who require longterm administration of antipsychotics to manage, for example, schizophrenia, clinicians are recommended to avoid initiation of these agents for at least 2 weeks after NMS resolution and to select a different antipsychotic that blocks dopamine less potently.
Malignant Catatonia
Catatonia is a syndrome of psychomotor disturbances that in its severe form, termed malignant catatonia, can present very similarly to NMS and serotonin syndrome. In fact, some consider NMS a variant of malignant catatonia caused by antipsychotic medications. 28 Three main neurobiological pathways may be involved in the development of malignant catatonia. Decreased GABA A activity, NMDA hyperactivity, and alterations in the dopamine pathway are thought to play a role in malignant catatonia development. Mood disorders, schizophrenia, metabolic disturbances, endocrinopathies, viral infections, heat stroke, autoimmune diseases, illicit drugs, benzodiazepine withdrawal, seizure or developmental disorder, and neurological conditions may all precipitate catatonia. 29 , 30 A few nonpsychiatric medications have been identified in case reports as the cause of catatonia, including minocycline, clarithromycin, azithromycin, and amoxicillin. 30 Signs of catatonia are variable and include mutism, posturing, negativism, waxy flexibility, hyperactivity, disorganized speech, strange mannerisms, and combativeness. 29 , 31 The BushFrancis Catatonia Rating Scale quantifies 23 individual symptoms for screening of catatonia and provides a standardized method for clinical examination ( Table 3 ) . 19 Malignant catatonia is a subtype of catatonia characterized by extreme agitation, hyperthermia, autonomic instability, delirium, and rigidity. Catatonia is typically associated with psychiatric illness with an estimated incidence of 7% to 38% in psychiatric patients, although it can also occur in other settings or patient populations. Studies have estimated the incidence of catatonia in general medical patients with psychiatric consults at 2% to 3%; however, this diagnosis is often difficult to identify and may be underestimated. 28 Although uncommon, malignant catatonia may be life-threatening if present. Early on the death rate of malignant catatonia was estimated at 75% to 100%, but since the 1980s the death rate has fallen to 9% of reported cases. 30 Treatment of malignant catatonia is focused on identifying the underlying cause, providing supportive care, and treating symptoms with medications that target the GABA A , NMDA, and dopamine pathways. Special attention to limiting morbidity from immobility, including prevention of pressure ulcers, rhabdomyolysis, and deep vein thrombosis, and ensuring adequate nutrition are essential supportive cares for catatonia. First-line treatments for malignant catatonia include benzodiazepines and ECT. Benzodiazepines target the GABA A pathway and correct deficiencies of GABA function to reverse symptoms. A "benzodiazepine challenge" with lorazepam provides dramatic clinical improvement within minutes of administration and may be helpful in supporting a diagnosis of catatonia. Intravenous administration of lorazepam may be required initially as a result of patient inability to take oral medications, but any route is acceptable. Starting doses of lorazepam may be 1 to 2 mg IV or by mouth every 4 to 12 hours, but doses of 12 to 16 mg/d or higher may be required in some patients. 30 Zolpidem is a GABA A agonist that has also been shown to be effective in case reports for treatment of catatonia. It has a quick onset of 15 to 30 minutes but lasts only 3 to 4 hours. Typical starting doses of zolpidem are 10 mg by mouth 3 times daily. Electroconvulsive therapy has been shown to be effective in benzodiazepine-refractory or severe malignant catatonia. 30 When a life-threatening catatonic state occurs, emergent ECT often results in rapid improvement via unclear mechanisms. Other therapies that may be considered for treatment-resistant catatonia include NMDA antagonists such as amantadine or memantine and antiepileptics such as topiramate, carbamazepine, and valproic acid; however, these therapies may take days to weeks to see maximal effect. Antipsychotics should generally be avoided in catatonia as a result of the high risk for precipitating NMS in these patients. Rarely, atypical antipsychotics with weak dopamine antagonist properties (eg, quetiapine) may be considered in specific situations for managing catatonia, often to treat an underlying psychiatric illness. 30 Antipsychotics that cause a greater degree of dopamine antagonism (ex. haloperidol, risperidone) should be avoided in catatonia.
Conclusion
Psychiatric emergencies, including DT, serotonin syndrome, NMS, and malignant catatonia, are potentially fatal if unidentified or untreated. Critical care nurses play a key role in identifying the development of signs or symptoms associated with these conditions. Familiarity with medications or substances associated with these conditions can help expedite the recognition and treatment of these potentially life-threatening situations.
